Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform
OV101 (gaboxadol) in Neurodevelopmental Disorders:
- Topline Results From Pivotal Phase 3 NEPTUNE Trial in Angelman Syndrome Expected in Mid-2020
- Results From Phase 2 Signal-Finding ROCKET Trial and SKY ROCKET Non-Interventional Data in Fragile X Expected by Early Q2 2020
OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE):
- Data from Randomized Phase 2 ELEKTRA Trial in Children with Dravet Syndrome or Lennox-Gastaut Syndrome Expected in 2H 2020
- Initial Data from Phase 2 ARCADE Trial in Dup15q Syndrome or CDKL5 Deficiency Disorder Expected in Q1 2020
- Additional Clinical Data From ENDYMION Open Label Extension Study Expected in Q1 2020
“Our focus in 2019 was on execution, building our senior leadership team and strengthening our balance sheet. As we look ahead to 2020, we enter the year in a strong financial position and will start to realize the potential impact that our hard work can deliver with multiple important clinical data readouts anticipated throughout the year,” said
For a full summary of 2020 clinical data milestones, please visit the Investors section of the
Clinical Data Readouts Expected in 2020
Gaboxadol for Angelman Syndrome
Ovid continues to enroll patients in the pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in mid-2020. The randomized, double-blind, placebo-controlled trial is designed to assess the effects of treatment with gaboxadol (oral, once-daily dosing) versus placebo over 12 weeks. The sole primary endpoint is change in overall score on the Clinical Global Impression-Improvement-Angelman syndrome (CGI-I-AS) scale.
NEPTUNE, if positive, will be part of a broad data set intended to support registrational filings for gaboxadol in the U.S. and rest of world. There are currently no other therapies in clinical development for Angelman syndrome, and if approved, gaboxadol would be the first medicine available for individuals with Angelman syndrome.
Soticlestat for Rare Developmental and Epileptic Encephalopathies (DEE)
Soticlestat is being evaluated in a comprehensive Phase 2 development program in DEE in collaboration with
Beyond the ENDYMION open-label extension study, Ovid and Takeda are also conducting the Phase 2 ARCADE and ELEKTRA trials in pediatric DEE patient populations.
Initial data from the Phase 2 ARCADE study are expected in Q1 2020. ARCADE is a multicenter, open-label, pilot study that will evaluate the treatment of soticlestat in patients ages 2 to 35 years old with refractory epileptic seizures associated with CDKL5 Deficiency Disorder (CDD) or Dup15q syndrome. The primary endpoint is the percent change in motor seizure frequency in patients treated with soticlestat by disorder.
Topline results from the Phase 2 ELEKTRA study are expected in 2H 2020. ELEKTRA is an international, multicenter, randomized, double-blind, placebo-controlled study that will evaluate the treatment of soticlestat in approximately 126 pediatric patients ages 2 to 17 years old with seizures associated with Dravet syndrome or Lennox-Gastaut syndrome (LGS). The primary endpoint is the percent change from baseline in seizure frequency in patients treated with soticlestat compared to placebo.
Despite the availability of medicines for epilepsy generally, there are few or no approved therapies for specific DEEs. Novel therapies are needed as current therapies fail to alter the course of the disease or address co-morbidities, and many patients suffer from resistant seizures despite treatment with multiple anti-epileptic drugs.
Gaboxadol for Fragile X Syndrome
Ovid expects results from the Phase 2 ROCKET trial and the SKY ROCKET non-interventional trial, in Fragile X syndrome by early Q2 2020.
The ROCKET trial is a signal-finding, randomized, double-blind, parallel-group trial to evaluate the safety, tolerability and efficacy of gaboxadol in males ages 13 to 22 with a confirmed diagnosis of Fragile X syndrome. The primary objective of the study is safety and tolerability of gaboxadol over 12 weeks of treatment in three different active-arm cohorts. The secondary objective is to evaluate changes in behavior after 12 weeks of treatment using the ABC-C scale adapted for Fragile X syndrome (ABC-FXS).
SKY ROCKET is a non-drug study of males ages 5 to 30 with a confirmed diagnosis of Fragile X to assess the suitability of scales for the measurement of behavior, sleep and functioning. This trial is designed to provide additional data on the key endpoints that are being explored in ROCKET and provide comparative data on the benefit offered by the standard-of-care.
There are no approved treatments for Fragile X syndrome.
2020 Educational Program
Ovid will continue to undertake a broad educational program to further review its pipeline and clinical endpoints relevant to neurodevelopmental disorders with key constituencies, including scientists, external clinician experts and patient advocacy groups.
About OV101 (gaboxadol)
Gaboxadol is believed to be the only delta (δ)-selective GABAA receptor agonist in development and the first investigational drug to specifically target the disruption of tonic inhibition, a central physiological process of the brain that is thought to be the underlying cause of certain neurodevelopmental disorders. Gaboxadol has been demonstrated in laboratory studies and animal models to selectively activate the δ-subunit of GABAA receptors, which are found in the extrasynaptic space (outside of the synapse), and thereby impact neuronal activity through modulation of tonic inhibition.
Ovid is developing gaboxadol for the treatment of Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and thereby address several core symptoms of these disorders. In both these syndromes, the underlying pathophysiology includes disruption of tonic inhibition modulated through the δ-subunit of GABAA receptors. In preclinical studies, it was observed that gaboxadol improved symptoms of Angelman syndrome and Fragile X syndrome. This compound has also previously been tested in more than 4,000 patients (more than 1,000 patient-years of exposure) and was observed to have favorable safety and bioavailability profiles. In 2018, Ovid announced the successful completion of its Phase 2 (STARS) trial of gaboxadol in adults and adolescents with Angelman syndrome. Ovid is conducting a pivotal Phase 3 clinical trial in Angelman syndrome (NEPTUNE) as well as a Phase 2 signal-finding clinical trial in Fragile X syndrome (ROCKET).
The FDA has granted Orphan Drug and Fast Track designations for gaboxadol for both the treatment of Angelman syndrome and Fragile X syndrome.
About OV935/TAK935 (soticlestat)
Soticlestat is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity. To Ovid’s knowledge, soticlestat is the only molecule with this mechanism of action in clinical development as an anti-epileptic drug (AED).
Ovid and Takeda are conducting a comprehensive Phase 2 clinical development program with soticlestat in people with Developmental and Epileptic Encephalopathies (DEE), a heterogeneous group of rare highly-refractory epilepsy syndromes that encompasses Dravet syndrome, Lennox-Gastaut syndrome (LGS), and others.
For more information on Ovid, please visit http://www.ovidrx.com/.
This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: advancing and commercializing Ovid’s product candidates, progress, timing, scope and the potential therapeutic benefits based on results of clinical trials for Ovid’s product candidates; and the anticipated reporting schedule of clinical data regarding Ovid’s product candidates. You can identify forward-looking statements because they contain words such as “will,” “believes” and “expects” and similar expressions intended to identify statements about the future. Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the
Investors and Media:
Investor Relations & Public Relations
Burns McClellan, Inc.
Source: Ovid Therapeutics Inc.